Microbial Heparin Production via Aerobic Granular Sludge
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing biomedical compounds like heparin and glycosaminoglycans face challenges due to structural complexity, raw material shortages, and low product yields, with existing microbial and chemical synthesis techniques being inefficient and costly.
Innovation Solution
A method involving the growth of bacteria in aerobic granular sludge reactors to produce heparin-like polymers and sialic acids, utilizing extracellular polymeric substances (EPS) as a matrix, which allows for high-yield extraction of these compounds without the need for extensive purification processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If heparin is produced from animal tissues (pig intestines, cattle lungs), then the product meets pharmaceutical grade requirements, but raw material shortages and structural complexity lead to low production yields
Solution Approach 1:
The patent replaces expensive, limited animal tissues with readily available microbial cells (E. coli K5) that can be continuously cultured. The microbial production system uses simple, inexpensive media components and can be scaled up without depending on animal slaughter byproducts, effectively substituting a depleted resource with a renewable one.
Solution Approach 2:
The patent modifies the production parameters by changing the biological source from animal tissues to microorganisms. By using E. coli K5 under controlled fermentation conditions with optimized media composition (containing glucose, amino acids, vitamins, and minerals), the system achieves consistent high-yield production of heparosan with controlled molecular weight and sulfation patterns.
2Productivity
If chemical synthesis methods are used to produce heparin, then structural complexity can be addressed, but numerous synthetic steps result in low product yields and high costs
Solution Approach 1:
The patent replaces complex chemical synthesis mechanisms with biological synthesis mechanisms. Instead of using multiple chemical reagents and catalysts to build the heparin structure step-by-step, the system employs E. coli K5's native biosynthetic pathways (modified through genetic engineering) to naturally produce heparosan, which is then converted to heparin through controlled sulfation. This biological approach simplifies the overall process while maintaining structural complexity.
Solution Approach 2:
The patent utilizes the self-organizing capability of biological systems. E. coli K5 cells automatically perform the complex tasks of assembling disaccharide units, linking them into polysaccharide chains, and controlling molecular weight distribution through their inherent enzymatic machinery. This eliminates the need for manual intervention in each synthesis step and reduces process complexity.
3Manufacturing precision
If recombinant strategies are used to convert heparosan to heparin, then product structure can be optimized, but the process becomes time-consuming and expensive
Solution Approach 1:
The patent combines multiple functions into a single integrated microbial production system. E. coli K5 is genetically engineered to simultaneously perform heparosan synthesis and initiate the conversion to heparin structure within the same cellular environment. This merging of biosynthetic pathways eliminates the need for separate, sequential processing steps and reduces overall production time while maintaining structural precision.
Solution Approach 2:
The patent performs preliminary genetic engineering of E. coli K5 to pre-establish the biosynthetic pathways needed for heparin production. The microorganisms are pre-adapted with necessary enzymes and metabolic routes before production begins, allowing them to directly synthesize structured heparin without requiring extensive post-production modification or purification steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the reliable production of high-purity heparin and sialic acid compounds, improving yield and reducing production costs by leveraging the natural biosynthesis capabilities of microorganisms in controlled reactor environments.
Implementation Method 1
leveraging the natural biosynthesis capabilities of microorganisms in controlled reactor environments
Data Source
AI summary
The present invention is in the field of a method for production of biomedical compounds by enrichment cultures of microorganisms, and a product obtainable by said methods. The microorganisms are grown in a batch reactor, a continuous reactor, a semi-continuous reactor, such as a Nereda® reactor.